{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:37:55Z","timestamp":1773758275427,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The standard of care for newly\u2010diagnosed unfit patients with acute myeloid leukemia (AML) is venetoclax (VEN) with azacitidine (AZA). In the phase 3 trial, before remission, AZA was given with 28\u2009days of VEN. This regimen is myelosuppressive; therefore, many decrease VEN duration before and\/or after initial response assessment. We report our center's outcomes administering 28\u2009days of VEN preremission, and in most cases, postremission, relying on other strategies to reduce cytopenias. All newly\u2010diagnosed patients with AML treated outside of a clinical trial with VEN\/AZA for &gt;\u20097\u2009days at our center from 2018 to 2024 were reviewed. 134 patients met inclusion criteria; median age was 70\u2009years (interquartile range [IQR] 64\u201376), 57% male, and 63% had European LeukemiaNet adverse risk AML (85\/134). Overall response rate (including complete remission and complete remission with incomplete hematologic recovery) was 87\/134 (64.9%). Median cycles completed was 2 (IQR 1\u20133, range 0\u201326), with 117 (87%) completing \u2265\u20091\u2009cycle with a response assessment. Median duration of cycles 1\u20135 was 42\u2009days. Median overall survival was 381\u2009days. Prior to response assessment, 113\/117 (96.6%) received 28\u2009days of VEN. Postresponse, 17\/81 (21.0%) had a VEN reduction (in duration or dose). Grade \u2265\u20093 neutropenia or thrombocytopenia was higher in cycle 1 than in similar studies, without differences in transfusion needs or infectious complications. Hematologic toxicities improved with subsequent cycles. Serial cycles with 28\u2009days of VEN can be administered pre\u2010 and postremission with higher early myelosuppression but similar transfusion and infection rates compared to studies of reduced VEN duration.<\/jats:p>","DOI":"10.1002\/ajh.70231","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T11:40:53Z","timestamp":1770982853000},"page":"728-735","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tolerability and Outcomes With Serial Cycles of 28\u2009Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia"],"prefix":"10.1002","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1834-6400","authenticated-orcid":false,"given":"Michael K.","family":"Jones","sequence":"first","affiliation":[{"name":"Divisions of Hematology and Medical Oncology University of Colorado School of Medicine  Aurora Colorado USA"},{"name":"Department of Medicine University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8428-1976","authenticated-orcid":false,"given":"Jesse","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7469-6012","authenticated-orcid":false,"given":"Megan","family":"Connor","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3427-9997","authenticated-orcid":false,"given":"Katherine","family":"Julian","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Rezac","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsey","family":"Marciano","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Tobin","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2397-2772","authenticated-orcid":false,"given":"Grace","family":"Bosma","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7769-9678","authenticated-orcid":false,"given":"Diana","family":"Abbott","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelyn","family":"Anttila","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connor","family":"Sohalski","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayele","family":"Belachew","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9745-9595","authenticated-orcid":false,"given":"Christine","family":"McMahon","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5523-6561","authenticated-orcid":false,"given":"Andrew","family":"Kent","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9503-5019","authenticated-orcid":false,"given":"Maria","family":"Amaya","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9903-5021","authenticated-orcid":false,"given":"Mathew G.","family":"Angelos","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A.","family":"Gutman","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6519-4860","authenticated-orcid":false,"given":"Daniel A.","family":"Pollyea","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0313"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001239"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024009"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025834"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01269-x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2293512"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200013"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-209246"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05102-y"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27180"},{"key":"e_1_2_10_13_1","unstructured":"M. A.\u2010O.Kanaya M.Onozawa T.Matsukawa et\u00a0al. \u201cComparable Outcomes With 14\u2010 21\u2010 or Standard 28\u2010Day Venetoclax in the First Cycle of Azacitidine\u2010Venetoclax in Untreated Acute Myeloid Leukemia: Real\u2010World Experience From the Hokkaido Leukemia Net \u201d(2044\u20105385 (Electronic))."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011757"},{"key":"e_1_2_10_15_1","volume-title":"Prescribing Information for VENCLEXTA (Venetoclax)","author":"USFDA","year":"2020"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27246"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26692"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002841"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2964"},{"key":"e_1_2_10_20_1","unstructured":"P.Fenaux G. J.Mufti E.Hellstr\u00f6m\u2010Lindber et\u00a0al. \u201cAzacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia \u201d(1527\u20107755 (Electronic))."},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024944"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac486"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.01.003"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.9151"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01270-4"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70231","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.70231","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T12:02:32Z","timestamp":1773748952000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.70231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/ajh.70231"],"URL":"https:\/\/doi.org\/10.1002\/ajh.70231","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"2025-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}